Bibliography | CPRD

Research using CPRD data has informed drug safety guidance and clinical practice and resulted in over 2,300 peer-reviewed publications.

The CPRD bibliography is updated on a monthly basis (last updated 4 September 2019) and papers are listed below and in the PDF below.

If you have published papers using CPRD data which are not included in this list, please contact us at enquiries@cprd.com so that we can update the bibliography.

Download:

CPRD bibliography

CPRD bibliography

(PDF, 3MB, 189 pages)

Export 19 results:

Author Title Type [ Year

]

Filters: Author is Strom, B. L. [Clear All Filters]

2017

L. V. Re, Carbonari, D. M., Saine, M. E., Newcomb, C. W., Roy, J. A., Liu, Q., Wu, Q., Cardillo, S., Haynes, K., Kimmel, S. E., Reese, P. P., Margolis, D. J., Apter, A. J., Reddy, K. R., Hennessy, S., Bhullar, H., Gallagher, A. M., Esposito, D. B., and Strom, B. L., “Postauthorization safety study of the DPP-4 inhibitor saxagliptin: a large-scale multinational family of cohort studies of five outcomes”, BMJ Open Diabetes Res Care, vol. 5, p. e000400, 2017.

M. E. Saine, Gizaw, M., Carbonari, D. M., Newcomb, C. W., Roy, J. A., Cardillo, S., Esposito, D. B., Bhullar, H., Gallagher, A. M., Strom, B. L., and , “Validity of diagnostic codes to identify hospitalizations for infections among patients treated with oral anti-diabetic drugs”, Pharmacoepidemiol Drug Saf, 2017.

2015

M. E. Saine, Carbonari, D. M., Newcomb, C. W., Nezamzadeh, M. S., Haynes, K., Roy, J. A., Cardillo, S., Hennessy, S., Holick, C. N., Esposito, D. B., Gallagher, A. M., Bhullar, H., Strom, B. L., and , “Determinants of saxagliptin use among patients with type 2 diabetes mellitus treated with oral anti-diabetic drugs”, BMC Pharmacol Toxicol, vol. 16, p. 8, 2015.

D. M. Carbonari, Saine, M. E., Newcomb, C. W., Blak, B., Roy, J. A., Haynes, K., Wood, J., Gallagher, A. M., Bhullar, H., Cardillo, S., Hennessy, S., Strom, B. L., and , “Use of demographic and pharmacy data to identify patients included within both the Clinical Practice Research Datalink (CPRD) and The Health Improvement Network (THIN)”, Pharmacoepidemiol Drug Saf, vol. 24, pp. 999-1003, 2015.

2012

C. E. Leonard, Freeman, C. P., Newcomb, C. W., Reese, P. P., Herlim, M., Bilker, W. B., Hennessy, S., and Strom, B. L., “Proton pump inhibitors and traditional nonsteroidal anti-inflammatory drugs and the risk of acute interstitial nephritis and acute kidney injury”, Pharmacoepidemiol Drug Saf, vol. 21, pp. 1155-72, 2012.

V. 3rd. Lo Re, Haynes, K., Ming, E. E., J. Ives, W., Horne, L. N., Fortier, K., Carbonari, D. M., Hennessy, S., Cardillo, S., Reese, P. P., Reddy, K. R., Margolis, D., Apter, A., Kimmel, S. E., Roy, J., Freeman, C. P., Razzaghi, H., Holick, C. N., Esposito, D. B., van Staa, T. P., Bhullar, H., and Strom, B. L., “Safety of saxagliptin: rationale for and design of a series of postmarketing observational studies”, Pharmacoepidemiol Drug Saf, vol. 21, pp. 1202-15, 2012.

2009

J. H. Flory, Ellenberg, S., Szapary, P. O., Strom, B. L., and Hennessy, S., “Antidiabetic action of bezafibrate in a large observational database”, Diabetes Care, vol. 32, pp. 547-51, 2009.

2008

J. D. Lewis, Gelfand, J. M., Troxel, A. B., Forde, K. A., Newcomb, C., Kim, H., Margolis, D. J., and Strom, B. L., “Immunosuppressant medications and mortality in inflammatory bowel disease”, Am J Gastroenterol, vol. 103, pp. 1428-35; quiz 1436, 2008.

2007

J. M. Gelfand, Troxel, A. B., Lewis, J. D., Kurd, S. K., Shin, D. B., Wang, X., Margolis, D. J., and Strom, B. L., “The risk of mortality in patients with psoriasis: results from a population-based study”, Arch Dermatol, vol. 143, pp. 1493-9, 2007.

2006

A. J. Apter, Kinman, J. L., Bilker, W. B., Herlim, M., Margolis, D. J., Lautenbach, E., Hennessy, S., and Strom, B. L., “Is there cross-reactivity between penicillins and cephalosporins?”, Am J Med, vol. 119, pp. 354.e11-9, 2006.

2005

J. D. Lewis, Bilker, W. B., Weinstein, R. B., and Strom, B. L., “The relationship between time since registration and measured incidence rates in the General Practice Research Database”, Pharmacoepidemiol Drug Saf, vol. 14, pp. 443-51, 2005.

2004

S. Hennessy, Bilker, W. B., Knauss, J. S., Kimmel, S. E., Margolis, D. J., Morrison, M. F., Reynolds, R. F., Glasser, D. B., and Strom, B. L., “Comparative cardiac safety of low-dose thioridazine and low-dose haloperidol”, Br J Clin Pharmacol, vol. 58, pp. 81-7, 2004.

A. J. Apter, Kinman, J. L., Bilker, W. B., Herlim, M., Margolis, D. J., Lautenbach, E., Hennessy, S., and Strom, B. L., “Represcription of penicillin after allergic-like events”, J Allergy Clin Immunol, vol. 113, pp. 764-70, 2004.

J. D. Lewis, Aberra, F. N., Lichtenstein, G. R., Bilker, W. B., Brensinger, C., and Strom, B. L., “Seasonal variation in flares of inflammatory bowel disease”, Gastroenterology, vol. 126, pp. 665-73, 2004.

2003

B. L. Strom, Schinnar, R., Apter, A. J., Margolis, D. J., Lautenbach, E., Hennessy, S., Bilker, W. B., and Pettitt, D., “Absence of cross-reactivity between sulfonamide antibiotics and sulfonamide nonantibiotics”, N Engl J Med, vol. 349, pp. 1628-35, 2003.

2002

D. J. Margolis, Bilker, W., Knauss, J., Baumgarten, M., and Strom, B. L., “The incidence and prevalence of pressure ulcers among elderly patients in general medical practice”, Ann Epidemiol, vol. 12, pp. 321-5, 2002.

J. D. Lewis, Brensinger, C., Bilker, W. B., and Strom, B. L., “Validity and completeness of the General Practice Research Database for studies of inflammatory bowel disease”, Pharmacoepidemiol Drug Saf, vol. 11, pp. 211-8, 2002.

2001

J. D. Lewis, Bilker, W. B., Brensinger, C., Deren, J. J., Vaughn, D. J., and Strom, B. L., “Inflammatory bowel disease is not associated with an increased risk of lymphoma”, Gastroenterology, vol. 121, pp. 1080-7, 2001.

[Page last reviewed 6 September 2019]